Open AccessDifferential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine
Author(s) -
Jenny S Maron,
Michelle Conroy,
Vivek Naranbai,
Upeka Samarakoon,
Tina Motazedi,
Jocelyn R. Farmer,
Esther E. Freeman,
Aleena Banerji,
Yannic C. Bartsch,
David Gregory,
Mark C. Poznansky,
Galit Alter,
Kimberly G. Blumenthal
Publication year - 2022
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiac107
Subject(s) - immunology , coronavirus , vaccination , antibody , virology , immunoglobulin e , medicine , respiratory system , antigen , biology , disease , covid-19 , infectious disease (medical specialty)
Allergic symptoms after messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines occur in up to 2% of recipients. Compared to nonallergic controls (n = 18), individuals with immediate allergic reactions to mRNA COVID-19 vaccines (n = 8) mounted lower immunoglobulin G1 (IgG1) to multiple antigenic targets in severe acute respiratory syndrome coronavirus 2 spike following vaccination, with significantly lower IgG1 to full-length spike (P = .04). Individuals with immediate allergic reactions to mRNA COVID-19 vaccines bound Fcγ receptors similarly to nonallergic controls. Although there was a trend toward an overall reduction in opsonophagocytic function in individuals with immediate allergic reactions compared to nonallergic controls, allergic patients produced functional antibodies exhibiting a high ratio of opsonophagocytic function to IgG1 titer.